Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
2000
Trial Sponsor
Clinical Trial Start Date
February 14, 2022
0Primary Completion Date
February 7, 2025
0Study Completion Date
February 7, 2025
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
PTC9230
Interventional Trial Phase
Phase 30
Participating Facility
Official Name
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria0
Last Updated
December 8, 2023
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
